Eli Wallace, BridgeBio Oncology Therapeutics CEO

Bridge­Bio spins out on­col­o­gy unit with $200M in back­ing for RAS as­sets

Bridge­Bio, a biotech known for its mod­el of set­ting up sub­sidiaries to house its R&D pro­grams, is split­ting off its on­col­o­gy unit with $200 mil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.